These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 23076151

  • 1. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM, Kugel CH, Dadpey N, Shao Y, Abel EV, Aplin AE.
    J Biol Chem; 2012 Dec 07; 287(50):41797-807. PubMed ID: 23076151
    [Abstract] [Full Text] [Related]

  • 2. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
    Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB.
    J Biol Chem; 2012 Aug 10; 287(33):28087-98. PubMed ID: 22730329
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ, Le K, Hartsough EJ, Aplin AE.
    Pigment Cell Melanoma Res; 2014 May 10; 27(3):479-84. PubMed ID: 24422853
    [Abstract] [Full Text] [Related]

  • 4. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.
    Nature; 2010 Dec 16; 468(7326):973-7. PubMed ID: 21107323
    [Abstract] [Full Text] [Related]

  • 5. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC.
    Oncotarget; 2016 May 24; 7(21):30907-23. PubMed ID: 27127178
    [Abstract] [Full Text] [Related]

  • 6. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M, Antoun G, Speicher P, Adams B, Turley R, Augustine C, Tyler D, Ali-Osman F.
    J Biol Chem; 2014 Oct 03; 289(40):27714-26. PubMed ID: 25063807
    [Abstract] [Full Text] [Related]

  • 7. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
    Conrad WH, Swift RD, Biechele TL, Kulikauskas RM, Moon RT, Chien AJ.
    Cell Cycle; 2012 Oct 15; 11(20):3724-30. PubMed ID: 22895053
    [Abstract] [Full Text] [Related]

  • 8. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB.
    Nature; 2011 Nov 23; 480(7377):387-90. PubMed ID: 22113612
    [Abstract] [Full Text] [Related]

  • 9. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.
    Le K, Blomain ES, Rodeck U, Aplin AE.
    Pigment Cell Melanoma Res; 2013 Jul 23; 26(4):509-17. PubMed ID: 23490205
    [Abstract] [Full Text] [Related]

  • 10. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.
    Nature; 2010 Dec 16; 468(7326):968-72. PubMed ID: 21107320
    [Abstract] [Full Text] [Related]

  • 11. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG.
    Proc Natl Acad Sci U S A; 2016 Nov 22; 113(47):13456-13461. PubMed ID: 27834212
    [Abstract] [Full Text] [Related]

  • 12. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J.
    Cancer Res; 2008 Jun 15; 68(12):4853-61. PubMed ID: 18559533
    [Abstract] [Full Text] [Related]

  • 13. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
    Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S.
    PLoS One; 2015 Jun 15; 10(9):e0138210. PubMed ID: 26405815
    [Abstract] [Full Text] [Related]

  • 14. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
    Shao Y, Aplin AE.
    Cell Death Differ; 2012 Dec 15; 19(12):2029-39. PubMed ID: 22858545
    [Abstract] [Full Text] [Related]

  • 15. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.
    Clin Cancer Res; 2013 Feb 01; 19(3):657-67. PubMed ID: 23251002
    [Abstract] [Full Text] [Related]

  • 16. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G.
    Cancer Res; 2012 Feb 15; 72(4):969-78. PubMed ID: 22205714
    [Abstract] [Full Text] [Related]

  • 17. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.
    Nature; 2010 Mar 18; 464(7287):431-5. PubMed ID: 20130576
    [Abstract] [Full Text] [Related]

  • 18. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM.
    Biochem Pharmacol; 2015 May 01; 95(1):16-27. PubMed ID: 25795251
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.
    J Clin Oncol; 2013 May 10; 31(14):1767-74. PubMed ID: 23569304
    [Abstract] [Full Text] [Related]

  • 20. Copper is required for oncogenic BRAF signalling and tumorigenesis.
    Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ, Counter CM.
    Nature; 2014 May 22; 509(7501):492-6. PubMed ID: 24717435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.